SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following constructive discussions with the FDA regarding a resubmission path for ANKTIVA in bladder cancer, complemented by significant international approvals and strategic partnerships like those recently established in Saudi Arabia for broader cancer indications. This development, coupled with high short interest, is fueling widespread community excitement about a potential paradigm shift in oncology and intense speculation regarding a short squeeze amidst growing calls for expedited access to these innovative treatments.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending as market participants react to heightened geopolitical tensions, specifically former President Trump's recent tariff threats against NATO allies over Greenland and an anticipated Supreme Court ruling on presidential tariff authority. This has sparked a fierce debate among investors, with some advocating to "buy the dip" and anticipating a rapid "Taco Trade" rebound, while others warn of a significant market correction. Adding to the volatility are concerns surrounding Japan's bond market instability, creating a complex and uncertain trading environment.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending after announcing a non-exclusive license agreement with Pfizer for its Matrix-M adjuvant, providing significant validation for the technology. This deal, building on previous collaborations, is driving community excitement and fueling discussions about the adjuvant's potential applications and the company's future partnerships amidst notable short interest.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as former President Trump's renewed threats of tariffs on NATO allies, particularly over the acquisition of Greenland, spark fears of a trade war with Europe. This escalating geopolitical tension is causing widespread market jitters and calls for caution, though many investors are also discussing it as a potential "buy the dip" opportunity for growth stocks.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares ETF (GLD) is trending strongly as renewed geopolitical tensions, including recent tariff threats concerning European countries over Greenland, fuel a broad flight to safety. The community views gold as a crucial hedge against eroding fiat currency confidence and economic instability, driving prices to consistent new highs. Many are discussing significant further appreciation as these global uncertainties persist.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending amid intense debate surrounding the Federal Reserve's independence, fueled by a federal probe into its Chair and the administration's aggressive policy maneuvers impacting bond markets. Investors are actively discussing whether long-term treasuries offer a crucial hedge against a potential economic slowdown or face further headwinds from escalating national debt and geopolitical uncertainty.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is currently a major talking point among investors, primarily driven by its upcoming earnings report and the proposed all-cash acquisition of Warner Bros. Discovery assets, which has sparked a debate over potential growth versus debt concerns. The community is closely watching for strong ad-tier performance and subscriber metrics, particularly after a previous tax-related earnings miss, with sentiment split on whether recent oversold conditions signal a significant rebound or continued volatility.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin ($APP) is experiencing significant volatility and a notable price decline following a new short report alleging the company's involvement in money laundering. This report has sparked intense debate among investors, with many attributing the drop to market manipulation and viewing it as a buying opportunity, while others express concern over the serious accusations despite recent bullish analyst upgrades.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to overwhelmingly positive data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis, with community discussions highlighting its strong efficacy in treatment-resistant patients. Investors are actively debating the potential for this novel oral ITK inhibitor to disrupt the significant atopic dermatitis market, fueling speculation of future partnerships or an acquisition and validating its broader immune-modulating platform.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is trending due to plans for a new rare earth facility in France, backed by French government support, and ongoing progress at its Stillwater magnet plant. The community is focused on USAR's crucial role in bolstering domestic critical mineral supply chains, citing geopolitical tensions and initiatives aimed at reducing reliance on China, and highlighting the company's future potential as it executes its mine-to-magnet strategy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cytek Biosciences (NASDAQ:CTKB) Shares Up 8.2% - Here's What Happened

Cytek Biosciences (NASDAQ:CTKB) Shares Up 8.2% - Here's Why...

Cytek Biosciences Preliminary Q4 Revenue Up 8%

(RTTNews) - Cytek Biosciences (CTKB) announced preliminary revenue results for the fourth quarter and full year ended December 31, 2025. Cytek expects total revenue for the full year 2025 to be...

Cytek Biosciences, Inc. (NASDAQ:CTKB) Receives Average Rating of "Hold" from Analysts

Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) has received a consensus recommendation of "Hold" from the eight research firms that are currently covering the firm, Marketbeat reports. Two...

Cytek Biosciences (NASDAQ:CTKB) Given New $5.00 Price Target at TD Cowen

TD Cowen lifted their price objective on shares of Cytek Biosciences from $4.00 to $5.00 and gave the company a "buy" rating in a research report on Thursday...

Cytek Biosciences, Inc. (NASDAQ:CTKB) Given Consensus Recommendation of "Hold" by Brokerages

Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) has earned a consensus rating of "Hold" from the seven research firms that are covering the stock, MarketBeat.com reports. Two investment...

Cytek Biosciences (NASDAQ:CTKB) Stock Price Up 7.2% - Here's What Happened

Cytek Biosciences (NASDAQ:CTKB) Trading 7.2% Higher - Time to Buy...

Cytek Biosciences (NASDAQ:CTKB) Sees Unusually-High Trading Volume - Time to Buy?

Cytek Biosciences (NASDAQ:CTKB) Sees Large Volume Increase - Here's Why...

Cytek Biosciences (NASDAQ:CTKB) Shares Gap Up - Time to Buy?

Cytek Biosciences (NASDAQ:CTKB) Shares Gap Up - Here's What Happened...

Cytek Biosciences (NASDAQ:CTKB) Price Target Lowered to $7.50 at Piper Sandler

Piper Sandler dropped their target price on Cytek Biosciences from $8.00 to $7.50 and set an "overweight" rating on the stock in a research report on Tuesday...

Cytek Biosciences (NASDAQ:CTKB) Trading Up 19.3% - Here's What Happened

Cytek Biosciences (NASDAQ:CTKB) Trading Up 19.3% - Here's What Happened...

Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. Its products include Cytek Aurora CS, Cytek Aurora, Cytek Northern Lights, and Cytek NL-CLC. The company was founded by Wenbin Jiang and Ming Yan in 1992 and is headquartered in Fremont, CA.

CTKB
Cytek BioSciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CTKB News

CTKBCytek BioSciences Inc